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Competitive and selective antagonism of P2Y1 receptors by
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The antagonist activity of N6-methyl 2'-deoxyadenosine 3',5'-bisphosphate (N6MABP) has been
examined at the phospholipase C-coupled P2Y1 receptor of turkey erythrocyte membranes. N6MABP
antagonized 2MeSATP-stimulated inositol phosphate hydrolysis with a potency approximately 20 fold
greater than the previously studied parent molecule, adenosine 3',5'-bisphosphate. The P2Y1 receptor
antagonism observed with N6MABP was competitive as revealed by Schild analysis (pKB=6.99+0.13).
Whereas N6MABP was an antagonist at the human P2Y1 receptor, no antagonist eect of N6MABP
was observed at the human P2Y2, human P2Y4 or rat P2Y6 receptors.
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Introduction Pharmacological classi®cation of natively ex-
pressed G protein-coupled P2Y receptors and unambiguous
de®nition of their physiological roles have been problematic
due to lack of selective receptor antagonists. The available
antagonists interact with non-receptor ATP-binding proteins
and antagonize both P2Y and P2X receptors (Ziganshin et al.,
1993; Bultmann & Starke, 1994; Harden et al., 1995; Charlton
et al., 1996).
The turkey erythrocyte has been utilized as a model cell-free
assay system for pharmacological and biochemical character-
ization of the P2Y1 receptor and its associated signalling
proteins (Boyer et al., 1996b). Using this test system we
recently identi®ed a group of molecules, the adenosine
bisphosphates, that exhibit partial agonist/antagonist activities
at the P2Y1 receptor (Boyer et al., 1996a). To identify
antagonist molecules that interact with higher anity with
the P2Y1 receptor, a series of adenosine bisphosphate
derivatives were synthesized with various adenine base- or
ribose-substitutions (Camaioni et al., 1998). In this paper we
describe the P2Y1 receptor activity and P2Y receptor subtype
speci®city of one of the most promising of these molecules, N6-
methyl 2'-deoxyadenosine 3',5'-bisphosphate (N6MABP or
MRS2179).
Methods Assay of P2Y receptor-promoted inositol lipid
hydrolysis Turkey erythrocytes were labelled with [3H]-
inositol and P2Y1 receptor-promoted phospholipase C activity
was determined in membranes prepared from these cells as
previously described (Boyer et al., 1996a). Inositol phosphate
accumulation in 1321N1 human astrocytoma cells expressing
the human P2Y1 receptor, the human P2Y2 receptor, the
human P2Y4 receptor or the rat P2Y6 receptor was determined
as previously described (Boyer et al., 1997).
Chemical synthesis N6MABP was prepared as previously
described (Camaioni et al., 1998). The chemical structure of
the phosphorylated nucleoside was veri®ed by use of 1H-n.m.r.
and 31P-n.m.r. techniques, as well as by high resolution fast
atomic bombardment mass spectroscopy.
Results A series of second generation molecules was
synthesized (Camaioni et al., 1998) based on our observation
that adenosine bisphosphates are P2Y1 receptor antagonists
(Boyer et al., 1996a). Absence of a hydroxyl in the 2' position
of these molecules resulted in analogues that, in contrast to the
originally studied adenosine bisphosphates, do not interact
with A1-adenosine receptors (data not shown). N6MABP
(insert in Figure 1a) was one of the most promising of these
molecules in preliminary studies, since no partial agonist
activity was observed at the turkey erythrocyte membrane
P2Y1 receptor and the eect of the full agonist 2MeSATP was
inhibited with an IC50 approximately 20 fold lower than that of
the parent compound 2'-deoxyadenosine 3',5'-bisphosphate
(data not shown). The nature of the antagonism was
determined by generating a series of concentration-eect
curves for 2MeSATP for stimulation of phospholipase C in
the presence of dierent concentrations of N6MABP.
N6MABP caused a parallel shift to the right of the
concentration-response curve for 2MeSATP (Figure 1a). In
contrast to the eects of reactive blue-2, suramin and PPADS
in the same assay system (Boyer et al., 1994), the eects of high
concentrations of N6MABP were completely surmountable by
high concentrations of 2MeSATP (Figure 1a). Schild analysis
(Figure 1b) con®rmed that the antagonism produced by
N6MABP was competitive with a pKb of 6.99+0.13 (n=3).
Identical antagonist properties were observed with the
positional isomer of N6MABP, N6-methyl 3'-deoxyadenosine
2',5'-bisphosphate (data not shown).
The selectivity of N6MABP was tested by examining its
eects at the human P2Y1, human P2Y2, human P2Y4 and rat
P2Y6 receptors (Figure 2). N6MABP completely blocked P2Y1
receptor-promoted stimulation of phospholipase C activity
induced by a near maximal concentration (100 nM) of
2MeSATP (Figure 2). This inhibition also was competitive
(data not shown). In contrast, no signi®cant inhibition was
observed of the response to 100 nM UTP at the human P2Y2
and P2Y4 receptors, or to 100 nM UDP at the P2Y6 receptor
(Figure 2).
Discussion The data presented here illustrate that N6MABP
is a high anity competitive antagonist at the P2Y1 receptor.
This antagonist also is remarkably selective since it apparently
does not block the three other cloned mammalian P2Y
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receptors. The high anity and receptor selectivity of
N6MABP make it unique among the molecules now available
for investigation of P2Y receptors. Although useful as P2
receptor antagonists, reactive blue 2 and suramin are well
known to interact with many nucleotide binding proteins in
addition to the P2 receptors, and they bind to multiple of the
known P2 receptors (Harden et al., 1995). Lambrecht and
coworkers have provided an important advance by introducing
PPADS (Lambrecht et al., 1992), which apparently exhibits
selectivity for P2 receptors over other types of proteins.
However, PPADS also antagonizes both P2X and P2Y
receptors, although it does exhibit selectivity for the P2Y1
receptor over other P2Y receptor subtypes (Ziganshin et al.,
1993; Boyer et al., 1994; Bultmann & Starke, 1994; Charlton et
al., 1996). A notable exception to the relatively non-selective
P2 receptor antagonists is the molecule, 2-propylthio-D-b,g-
dichloromethylene ATP (ARL 67085), which is a selective
antagonist of very high anity at the Gi/adenylyl cyclase-
linked P2Y receptor of platelets (Humphries et al., 1995). This
molecule does not block P2Y1 receptors, which prominently
distinguishes it from adenosine 3',5'-bisphosphate which
competitively blocks the P2Y1 receptor but does not interact
with the Gi/adenylyl cyclase-linked receptor of C6 rat glioma
cells (Boyer et al., 1996a).
A major advantage of N6MABP is that it is an adenine
nucleotide derivative in a group of second generation
molecules that have followed from the observation that
phosphate-substitution in the 2'- or 3'-position results in loss
of agonist activity at P2Y receptors without a coincident loss
of receptor anity. Discovery of antagonist activity in an
adenine nucleotide derivative places us in position to take
further advantage of the wide ranging structure activity studies
that have preceded on adenine nucleotide derivatives at the
P2Y1 receptor. Moreover, the pharmacological selectivity and
apparent anity of the adenosine bisphosphate derivative
demonstrated here should prove useful for pharmacological
resolution of the P2Y1 receptor in various mammalian
tissues.
Figure 2 Eects of N6MABP on mammalian P2Y receptors stably
expressed in 1321N1 human astrocytoma cells. [3H]-inositol-labelled
1321N1 human astrocytoma cells stably expressing the human P2Y1,
human P2Y2, human P2Y4 or rat P2Y6 receptors were incubated
with 100 nM 2MeSATP (P2Y1), 100 nM UTP (P2Y2 and P2Y4), or
100 nM UDP (P2Y6) in the absence or in the presence of 30 mM
N6MABP. The data are from a representative experiment repeated
three times.
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